Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The best drug sequencing of dacomitinib or osimertinib in patients with advanced or
metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung
cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy
of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with
classical or uncommon activating EGFR mutations. Efficacy of dacomitinib will be defined in
patients with asymptomatic or controlled brain metastases, special population eligible in
this clinical trial.